How is SUDA Pharmaceuticals (ASX:SUD) Placed for 2021?

  • January 18, 2021 11:07 AM AEDT
  • Team Kalkine
    Team Kalkine
    Team Kalkine
    16964 Posts

    Team Kalkine comprises of experts who understand various markets nuances and are enthusiastic and passionate to provide best possible offerings in the form of insights and stories. The team has rich experience of working across different markets with...

How is SUDA Pharmaceuticals (ASX:SUD) Placed for 2021?


  • SUDA Pharmaceuticals Limited (ASX:SUD) is anticipated to make significant progress in its product pipeline in 2021.
  • The healthcare company plans to secure new technologies that fit within its current areas of focus.
  • SUDA also intends to continue with the commercialisation of ZolpiMist® and advance the development of anagrelide during the year.

SUDA Pharmaceuticals Limited (ASX:SUD) had a number of positive events in 2020, achieving several significant milestones with regards to anagrelide and ZolpiMist® projects. Moreover, the Australian healthcare company opportunistically reviewed other assets, rebuilt investor confidence, and improved shareholder communications during the year.

Must Read: SUDA Pharmaceuticals (ASX:SUD) Delivers Impressive Performance in 2020

As SUDA marks its entry into 2021, the Company is expected to make further progress in its product pipeline while building its presence in current focus areas and executing on the significant programs.

With that said, let us take a deep dive into SUDA’s areas of interest for 2021:

Source, Evaluate and Acquire New Technologies

SUDA intends to continue with its efforts to secure new technologies in the future, which are expected to be developed internally. The Company plans to obtain technologies that fit within its current focus areas (oncology and central nervous system) to expand its existing portfolio.

Interestingly, SUDA’s leadership team holds extensive experience in acquiring, sourcing, and evaluating new technologies. Preliminary searches have identified several interesting technologies that the Company believes could enhance its present portfolio of products.

At present, SUDA is utilising its exclusive OroMist® technology to aadd value to a number of existing drugs.. With OroMist®, the Company is reformulating existing billion-dollar drugs for oral delivery, which can provide a faster path to market, which can create sizeable cost and time savings.

The OroMist® technology enables SUDA to develop low-risk oral sprays, which offer substantial advantages over pills or tablets.

ZolpiMist® Commercialisation

SUDA is continuing discussions with pharmaceutical companies to commercialise ZolpiMist® in different territories.

The Company is in the process of selecting its Australian partner to commercialise the product after the receipt of TGA (Therapeutics Goods Administration) approval last year. SUDA considers the TGA approval as a significant event that has occurred in the history of the Company.

Related Read: SUDA Reaches Major Milestone with Grant of TGA Approval for ZolpiMistTM, Stock Rallies Above 150%

Notably, SUDA will continue working with its existing partners – Teva, Mitsubishi Tanabe Pharma Korea and Mitsubishi Tanabe Pharma Singapore – to help with their regulatory submissions and commercialisation efforts concerning ZolpiMist®.

Anagrelide Formulation Stabilisation and Preclinical Studies

SUDA is deliberately progressing with the development of anagrelide as it believes a significant amount of value can be created by taking this program further along the development pathway. The Company is continuing with the optimisation of the anagrelide formulation in order to produce a pharmaceutical grade product.

It is worth noting that SUDA has received positive results from pre-clinical animal trials on anagrelide. The results indicated that an oral spray form of anagrelide could lower patients’ exposure to the cardiostimulatory intermediate, curbing unwanted side effects.

Read More at SUDA Reports Promising Results from Anagrelide’s Canine Pharmacokinetic Study

SUDA plans to complete the pre-clinical toxicology studies before embarking on clinical trials for anagrelide.

In addition to these fields of activity, SUDA also intends to manage costs, maintain shareholder communications, and focus on investor confidence in 2021. To attain its objectives, the Company recently announced a $2.76 million capital raising, strengthening its financial position. Consequently, the Company’s cash balance should allow the company to proceed with its development program for the next 12 months.

SUDA shares are trading at $0.042 as at 11:00 AM AEDT.


The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK